<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03568695</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO-2018-01</org_study_id>
    <nct_id>NCT03568695</nct_id>
  </id_info>
  <brief_title>Detection of Chlamydia Trachomatis, Neisseria Gonorrhoeae and Mycoplasma Genitalium by Real-time Multiplex Polymerase Chain Reaction (PCR) After Pooling Pharyngeal, Anorectal and Urinary Samples</brief_title>
  <acronym>ISTPOOL</acronym>
  <official_title>Detection of Chlamydia Trachomatis, Neisseria Gonorrhoeae and Mycoplasma Genitalium by Real-time Multiplex Polymerase Chain Reaction After Pooling Pharyngeal, Anorectal and Urinary Samples, in Men Who Have Sex With Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the sensitivity of detecting Chlamydia trachomatis, Neisseria
      gonorrhoeae and Mycoplasma genitalium by real-time multiplex PCR in a pooled analysis (i.e.
      gathering pharyngeal, anorectal and urinary samples) versus the standard of care (where a
      real-time multiplex PCR is made in each of the three samples).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients detected positive for one of the three (Sexually Transmitted Infection)STIs
      (Chlamydia trachomatis, Neisseria gonorrhoeae or Mycoplasma genitalium) on one site will be
      re-sampled twice at each of the three sites (pharynx, rectum, urine) before receiving
      antibiotics. Then, a real-time multiplex PCR will be performed on the pooled sample (merging
      pharyngeal, anorectal and urinary samples) versus on each of the three samples separately
      (i.e. standard of care) to compare both sensitivities.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2018</start_date>
  <completion_date type="Anticipated">June 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the sensitivity of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium detection in a pooled analysis</measure>
    <time_frame>Day 1</time_frame>
    <description>Sensitivity rates will be compared using non parametric statistical analysis. The pooling method will be considered as acceptable if the sensitivity reach at least 95%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of the strategies on the costs</measure>
    <time_frame>Day 1</time_frame>
    <description>Costs will include time of lab staff, DNA extraction, PCR material in the two strategies and related to 1000 patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chlamydia Trachomatis Infection</condition>
  <condition>Neisseria Gonorrheae Infection</condition>
  <condition>Mycoplasma Genitalium Infection</condition>
  <condition>Sensitivity</condition>
  <condition>Polymerase Chain Reaction</condition>
  <arm_group>
    <arm_group_label>Detected patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>If they agree to participate in the study, the patients detected for one or the other of the STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium) on one site, will have on day of result return, two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Two samples on each of the three sites (pharynx, rectum, urine)</intervention_name>
    <description>two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .</description>
    <arm_group_label>Detected patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient having provided a written consent;

          -  Patient age &gt; 18 years;

          -  Man who have sex with men tested positive for one the three STIs : Chlamydia
             trachomatis, Neisseria gonorrhoeae or Mycoplasma genitalium

          -  Covered by health insurance

        Exclusion Criteria:

          -  Being under tutorship

          -  Being deprived of liberty

          -  Patient who received antibiotic treatment prior to study inclusion and re-sampling
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry PRAZUCK, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR d'Orléans</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélie DESPUJOLS</last_name>
    <phone>0033238744071</phone>
    <email>aurelie.despujols@chr-orleans.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie TATSI TOTOUOM</last_name>
    <phone>0033238744086</phone>
    <email>elodie.tatsi-totouom@chr-orleans.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH de Niort</name>
      <address>
        <city>Niort</city>
        <zip>79021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon SUNDER, Dr</last_name>
      <email>simon.sunder@ch-niort.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR d'Orleans</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent HOCQUELOUX, Dr</last_name>
      <email>laurent.hocquelous@chr-orleans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwenael LE MOAL, Dr</last_name>
      <email>g.lemoal@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Laennec</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale PERFEZOU, Dr</last_name>
      <email>p.perfezou@ch-cornouaille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume GRAS, Dr</last_name>
      <email>guillaume.gras@me.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://cns.sante.fr/wp-content/uploads/2017/10/experts-vih_aes.pdf</url>
    <description>Rapport Morlat 2017</description>
  </link>
  <reference>
    <citation>Kacena KA, Quinn SB, Howell MR, Madico GE, Quinn TC, Gaydos CA. Pooling urine samples for ligase chain reaction screening for genital Chlamydia trachomatis infection in asymptomatic women. J Clin Microbiol. 1998 Feb;36(2):481-5.</citation>
    <PMID>9466763</PMID>
  </reference>
  <reference>
    <citation>La Ruche G, Le Strat Y, Fromage M, Berçot B, Goubard A, de Barbeyrac B, Sednaoui P, Cambau E, Lot F. Incidence of gonococcal and chlamydial infections and coverage of two laboratory surveillance networks, France, 2012. Euro Surveill. 2015 Aug 13;20(32):6-15.</citation>
    <PMID>26290487</PMID>
  </reference>
  <reference>
    <citation>Lewis JL, Lockary VM, Kobic S. Cost savings and increased efficiency using a stratified specimen pooling strategy for Chlamydia trachomatis and Neisseria gonorrhoeae. Sex Transm Dis. 2012 Jan;39(1):46-8. doi: 10.1097/OLQ.0b013e318231cd4a.</citation>
    <PMID>22183846</PMID>
  </reference>
  <reference>
    <citation>Kacena KA, Quinn SB, Hartman SC, Quinn TC, Gaydos CA. Pooling of urine samples for screening for Neisseria gonorrhoeae by ligase chain reaction: accuracy and application. J Clin Microbiol. 1998 Dec;36(12):3624-8.</citation>
    <PMID>9817885</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>September 6, 2019</last_update_submitted>
  <last_update_submitted_qc>September 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pooled analysis</keyword>
  <keyword>sensitivity</keyword>
  <keyword>men who have sex with men</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Chlamydia Infections</mesh_term>
    <mesh_term>Gonorrhea</mesh_term>
    <mesh_term>Mycoplasma Infections</mesh_term>
    <mesh_term>Pleuropneumonia</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

